CVM (CEL-SCI) E10: $-36.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVM CEL-SCI Corp CVM
19 GF Score
Price $1.18
! 2 Warning Signs
View Full Analysis

What is CEL-SCI E10?

CEL-SCI CVM -0.84% 19 E10 is $-36.33 as of Mar. 2026. GuruFocus rates CVM with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CEL-SCI's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.670. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-36.33 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 40.80% per year. During the past 5 years, the average E10 Growth Rate was 35.10% per year. During the past 10 years, the average E10 Growth Rate was 25.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of CEL-SCI was 40.80% per year. The lowest was -1.90% per year. And the median was 16.70% per year.

As of today (2026-07-25), CEL-SCI's current stock price is $1.18. CEL-SCI's E10 for the quarter that ended in Mar. 2026 was $-36.33. CEL-SCI's Shiller PE Ratio of today is .


CEL-SCI  (AMEX:CVM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CEL-SCI E10 Related Terms


CEL-SCI E10 Historical Data

* Premium members only.

The historical data trend for CEL-SCI's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI E10 Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -268.64 -198.08 -142.06 -86.16 -41.07

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.38 -50.92 -41.07 -43.22 -36.33

CVM vs OTLC, AEON, CLRB: E10 Comparison

For the Biotechnology subindustry, CEL-SCI's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Shiller PE Ratio falls into.


CVM
19GF Score
CEL-SCI Corp CVM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CEL-SCI's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.67/330.2130*330.2130
=-0.670

Current CPI (Mar. 2026) = 330.2130.

CEL-SCI Quarterly Data

per share eps CPI Adj_EPS
201606 -23.400 241.018 -32.060
201609 -4.800 241.428 -6.565
201612 9.600 241.432 13.130
201703 -34.500 243.801 -46.728
201706 -15.900 244.955 -21.434
201709 -17.100 246.819 -22.878
201712 -15.900 246.524 -21.298
201803 -9.300 249.554 -12.306
201806 -10.800 251.989 -14.153
201809 -21.000 252.439 -27.470
201812 0.600 251.233 0.789
201903 -6.600 254.202 -8.574
201906 -11.100 256.143 -14.310
201909 -3.900 256.759 -5.016
201912 -4.800 256.974 -6.168
202003 -7.500 258.115 -9.595
202006 -8.100 257.797 -10.375
202009 -3.900 260.280 -4.948
202012 -6.300 260.474 -7.987
202103 -8.400 264.877 -10.472
202106 -7.500 271.696 -9.115
202109 -5.700 274.310 -6.862
202112 -6.000 278.802 -7.106
202203 -6.900 287.504 -7.925
202206 -6.900 296.311 -7.689
202209 -6.300 296.808 -7.009
202212 -5.400 296.797 -6.008
202303 -5.700 301.836 -6.236
202306 -5.700 305.109 -6.169
202309 -4.800 307.789 -5.150
202312 -4.200 306.746 -4.521
202403 -4.200 312.332 -4.440
202406 -4.180 314.175 -4.393
202409 -2.800 315.301 -2.932
202412 -3.250 315.605 -3.400
202503 -2.330 319.799 -2.406
202506 -1.360 322.561 -1.392
202509 -0.761 324.800 -0.774
202512 -0.680 324.054 -0.693
202603 -0.670 330.213 -0.670

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-36.33 mean?
CEL-SCI (CVM) has a E10 of $-36.33 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CEL-SCI and its competitors.
Is CEL-SCI's E10 too high?
CEL-SCI's current E10 is $-36.33. Overall, CEL-SCI has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's E10 compare to OTLC and AEON?
CEL-SCI's E10 of $-36.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CEL-SCI and its competitors. CEL-SCI's current E10 is $-36.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (CVM) has a current E10 of $-36.33. The current E10 is $-36.33. CEL-SCI's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For CEL-SCI (CVM), the current E10 is $-36.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges LSR:Germany
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
19GF Score

Get the complete analysis for CVM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price